Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 5:2019:9698086.
doi: 10.1155/2019/9698086. eCollection 2019.

The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Tatiana M Reshetnyak  1   2 , Irina A Doroshkevich  3 , Natalia V Seredavkina  1 , Evgeny L Nasonov  4 , Igor V Maev  5 , Vasiliy I Reshetnyak  5
Affiliations

The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Tatiana M Reshetnyak et al. Int J Rheumatol. .

Abstract

Background: The nature and rate of gastric mucosal (GM) damage in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) remain to be among the unsolved problems.

Objective: To define the role of H. pylori and drugs in the development of GM damages in SLE and APS.

Methods: A study was conducted on 85 patients with SLE and APS. All the patients underwent esophagogastroduodenoscopy with targeted biopsy of the mucosa of the gastric body and antrum. The presence of H. pylori in the gastric biopsy specimens was determined using polymerase chain reaction.

Results: Endoscopic examination revealed that the patients with SLE and APS on admission had the following GM changes: antral gastritis (82.4%), erosions (24.7%), hemorrhages (8.2%), and pangastritis (8.2%). SLE and APS patients showed no direct correlation between the found GM damages and the presence of H. pylori. The use of glucocorticoid, low-dose acetylsalicylic acid, nonsteroidal anti-inflammatory drug, and anticoagulant in SLE and APS patients is accompanied by GM damage.

Conclusion: There was no evidence of the role of H. pylori in GM damage in the SLE and APS patients. More frequent detection of H. pylori was observed in anticoagulants or low-dose acetylsalicylic acid users than in glucocorticoids and nonsteroidal anti-inflammatory drugs ones.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lahita R. G. The clinical presentation of systemic lupus erythematosus. In: Lahita R. G., editor. Results of a Study of Patients with Systemic Lupus Erythematosus. San Diego, California, Calif, USA: Elsevier; 2004. pp. 435–444. (Systemic lupus erythematosus).
    1. Rahman A., Isenberg D. A. Systemic lupus erythematosus. The New England Journal of Medicine. 2008;358(9):929–939. doi: 10.1056/nejmra071297. - DOI - PubMed
    1. Reshetnyak T. M. Systemic lupus erythematosus. In: Badokin V. V., editor. Rheumatology. Mosco, Russia: Litterra; 2012. pp. 245–331. (chapter 10, Clinical lectures).
    1. Mok C. C. Investigations and management of gastrointestinal and hepatic manifestations of systemic lupus erythematosus. Best Practice and Research Clinical Rheumatology. 2005;19(5):741–766. doi: 10.1016/j.berh.2005.04.002. - DOI - PubMed
    1. Witt M., Zecher D., Anders H. J. Gastrointestinal manifestations associated with systemic lupus erythematosus. European Journal of Medical Research. 2006;11:253–260. - PubMed

LinkOut - more resources